Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies

References

• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3406–3413.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;14:64.
   Google Scholar
• Curigliano G, Shah RR. Safety and tolerability of phosphatidylinositol-3-kinase (PI3K) inhibitors in oncology. Drug Saf. 2019;42:247–262.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317–330. .
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329–341.
   PubMed Web of Science ®Google Scholar
• Fruman D, Cantley L. Idelalisib- A PI3Kδ inhibitor for B-cell cancers. N Engl J Med. 2014;370(11):1061–1062.
   PubMed Web of Science ®Google Scholar
• Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078–2088.
   PubMed Web of Science ®Google Scholar
• Ferrer G, Montserrat E. Critical molecular pathways in CLL therapy. Mol Med. 2018;24:9.
   PubMed Web of Science ®Google Scholar
• Ortiz-Madonado V, Garcia-Morillo M, Delgado J. The biology behind PI3K inhibition in chronic lymphocytic leukaemia. Ther Adv Hematol. 2015;6:25–36.
   PubMed Web of Science ®Google Scholar
• Zirlik K, Veelken H. Idelalisib. Recent Results Cancer Res. 2018;212:243-264.
   Google Scholar
• Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol. 2012;3:256.
   PubMed Web of Science ®Google Scholar
• JÁ FV, Casado E, de Castro J, et al. P13K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193–204.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Jin F, Sharma S, et al. Clinical pharmacokinetic and pharmacodynamic profile of idelalisib. Clin Pharmacokinet. 2016;55:33–45.
   PubMed Web of Science ®Google Scholar
• CHMP. Zydelig, INN-Idelalisib; 2016. [cited 2020 Mar 20]. Available from: www.ema.europa.eu/contact.
   Google Scholar
• Furman R, Sharman J, Coutre S, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118:3603–3612.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SEM, et al. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Webb HK, Chen H, Yu AS, et al. Clinical pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies. Blood. 2010;116:1774.
   Web of Science ®Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123:3406–3413.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, Flowers C, et al. Activity of idelalisib in high-risk follicular lymphoma with early relapse following front line immunochemotherapy. Blood. 2015;126:2744.
   Web of Science ®Google Scholar
• Miller BW, Przepiorka D, De Claro RA, et al. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res. 2015;21:1525–1529.
   PubMed Web of Science ®Google Scholar
• Martin P, Armas A, Gopal AK, et al. Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL). Blood. 2015;126:1543.
   Web of Science ®Google Scholar
• Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398–3405.
   PubMed Web of Science ®Google Scholar
• Zydelig Approval History [cited May 2020]. Available from: https://www.drugs.com/history/zydelig.html
   Google Scholar
• Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019 Jun;1(37):1391–1402. .
   Google Scholar
• Smith SM, Pitcher BN, Jung SH, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4:e176–e182.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Nastoupil LJ, Neelapu SS, et al. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015;125:3357–3359.
   PubMed Web of Science ®Google Scholar
• Barr PM, Saylors GB, Spurgeon SE, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127:2411–2415.
   PubMed Web of Science ®Google Scholar
• Jones JA, Robak T, Brown JR, et al., Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 4(3): e114–e126. 2017.
   PubMed Web of Science ®Google Scholar
• Zelenetz A, Barrientos J, Brown J, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18:297–311.
   Google Scholar
• Coutre SE, Flinn IW, de Vos S, et al. Idelalisib in combination with rituximab or bendamustine or both in patients with relapsed/refractory chronic lymphocytic leukemia. HemaSphere. 2018;2:e39.
   PubMedGoogle Scholar
• Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779–2786.
   PubMed Web of Science ®Google Scholar
• CHMP. Zydelig, INN-Idelalisib.; 2016. [cited 2020 Mar 20]. Available from: www.ema.europa.eu/contact.
   Google Scholar
• Salles G, Schuster SJ, De Vos S, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study. Haematologica. 2017;102:e156–e159.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203.
   PubMed Web of Science ®Google Scholar
• Brown JR, Zelenetz AD, Furman RR, et al. Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. Blood. 2017;130:3016.
   Web of Science ®Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION. [cited 2020 Mar 20]. Available from: www.fda.gov/medwatch.
   Google Scholar
• Cuneo A, Barosi G, Danesi R, et al. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. Hematol Oncol. 2019;37:3–14.
   PubMed Web of Science ®Google Scholar
• Haustraete E, Obert J, Diab S, et al. Idelalisib-related pneumonitis. Eur Respir J. 2016;128:195–203.
   Google Scholar
• Migault C, Lebrun D, Toubas O, et al. Pulmonary adverse events related to idelalisib therapy: A single centre experience. J Chemother. 2018;30(5):318–322. .
   PubMed Web of Science ®Google Scholar
• Sehn LH, Hallek M, Jurczak W, et al. A retrospective analysis of pneumocystis jirovecii pneumonia infection in patients receiving idelalisib in clinical trials. Blood. 2016;128:3705.
   Web of Science ®Google Scholar
• Chiumello D, Brochard L, Marini JJ, et al. Respiratory support in patients with acute respiratory distress syndrome: an expert opinion. Crit Care. 2017;21:240.
   PubMed Web of Science ®Google Scholar
• Weidner A-S, Panarelli NC, Geyer JT, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015;39:1661–1667.
   PubMed Web of Science ®Google Scholar
• De Weerdt I, Koopmans SM, Kater AP, et al. Incidence and management of toxicity associated with ibrutinib and idelalisib: A practical approach. Haematologica. 2017;102:1629–1639.
   PubMed Web of Science ®Google Scholar
• Louie CY, DiMaio MA, Matsukuma KE, et al. Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol. 2015;39:1653–1660.
   PubMed Web of Science ®Google Scholar
• Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918–2926.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016;128:331–336.
   PubMed Web of Science ®Google Scholar
• Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11:317–328.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Snyder AE, Carvajal RD, et al. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015;75:747–755.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Wulf GM, Barry WT, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017;28:512–518.
   PubMed Web of Science ®Google Scholar
• Saura C, Bendell J, Jerusalem G, et al. Phase lb study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res. 2014;20:1935–1945.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA News Alert: FDA approves new treatment for adults with relapsed follicular lymphoma. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-follicular-lymphoma
   Google Scholar
• Liu N, Rowley BR, Bull CO, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013;12:2319–2330.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Appleman LJ, Tolcher AW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:1928–1940.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2019;10:25711.
   Google Scholar
• Dong S, Guinn D, Dubovsky JA, et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood. 2014;124:3583–3586.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: A Phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. In: journal of Clinical Oncology. Am Soc Clin Oncol. 2019;37:912–922.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446–2455.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Fujiwara Y, Tamura K, et al. Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer. Invest New Drugs. 2017;35:37–46.
   PubMed Web of Science ®Google Scholar
• Vuylsteke P, Huizing M, Petrakova K, et al. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Ann Oncol. 2016;27:2059–2066.
   PubMed Web of Science ®Google Scholar
• Tamura K, Kodaira M, Shimizu C, et al. Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. Cancer Sci. 2018;109:1592–1601.
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Bell-McGuinn KM, Molina JR, et al. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015;21:1888–1895.
   PubMed Web of Science ®Google Scholar
• Massard C, Chi KN, Castellano D, et al. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. Eur J Cancer. 2017;76:36–44.
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Alsina M, Soares HP, et al. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol. 2017;12:775–785.
   PubMed Web of Science ®Google Scholar
• McRee AJ, Marcom PK, Moore DT, et al. A phase I trial of the PI3K inhibitor buparlisib combined with capecitabine in patients with metastatic breast cancer. Clin Breast Cancer. 2018;18:289–297.
   PubMed Web of Science ®Google Scholar
• Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:904–916.
   PubMed Web of Science ®Google Scholar
• Wise-Draper TM, Moorthy G, Salkeni MA, et al. A phase Ib study of the dual PI3K/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies. Target Oncol. 2017;12:323–332.
   PubMed Web of Science ®Google Scholar
• Powles T, Lackner MR, Oudard S, et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2016;34:1660–1668.
   PubMed Web of Science ®Google Scholar
• Dolly SO, Wagner AJ, Bendell JC, et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2016;22:2874–2884.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169–2178.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35:3898–3905.
   PubMed Web of Science ®Google Scholar
• Flinn I, Oki Y, Patel M, et al. A Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL. Blood. 2014;124:802.
   Web of Science ®Google Scholar
• Leong S, Moss RA, Bowles DW, et al. A phase I dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with erlotinib in patients with advanced solid tumors. Oncologist. 2017;22:1491–1499.
   PubMed Web of Science ®Google Scholar
• Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-kinase alpha-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol. 2018;36:1291–1299.
   PubMed Web of Science ®Google Scholar
• Stock S, Übelhart R, Schubert M-L, et al. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. Int J Cancer. 2019;145:1312–1324.
   PubMed Web of Science ®Google Scholar
• Bhatti M, Ippolito T, Mavis C, et al. Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. Oncotarget. 2018;9:21820–21830.
   PubMedGoogle Scholar
• Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-δ,g inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888–898. .
   PubMed Web of Science ®Google Scholar
• Sanchez VE, Nichols C, Kim HN, et al. Targeting PI3K signaling in acute lymphoblastic leukemia. Int J Mol Sci. 2019;20:e412.
   PubMed Web of Science ®Google Scholar
• Eldfors S, Kuusanmäki H, Kontro M, et al. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. Leukemia. 2017 Jan;31:51–57.
   PubMed Web of Science ®Google Scholar